Diabetes Care in The Netherlands: - Novo Nordisk

More documents

Recommendations

Info

Non-compliance is challenge of distant benefits and largerequiredNon-compliancebehaviouralis a challengechangeof distant benefits and largeWeak motivation tocomply• Motivation to change is typically limited: no sense of urgency– No feeling of illness (especially in early stages)– Acceptance of illness– Benefits of compliance are distant• Compliance creates a short–term risk of side effects– e.g. especially hyposExtensivebehavioural changerequired• Far reaching change in daily routines– Sleep times,– Diet– Exercising• Requires an adjustment in social life– Social pressure to engage in social activities not congruent with treatment– Environment may perceive the distance as an ‘excuse’ to avoid participation• Requires an advanced understanding of the disease– Complex intake schemes that are dependent on the context of daily activities– Need to develop a optimized personal routineSource:Apotheke und krankenhaus Ursachhen der Non-Compiance, Booz Booz && Company AnalysisBooz & Company 14 November 201152Prepared for Novo Nordisk45
Facilitated patient networks are successful in other distantdistant benefits benefits – high behavioural – high behavioural change conditions change conditionsChronic quadrangleConsequences versus behavior/technology dependencyMotivation to comply withbest known therapyWeakStrongTechnology dependent diseasesParkinson’sHIVPatients willprobably adhereChronic hepatitis BEpilepsyPatients will adhereDiseases with deferred consequencesAllergiesDisease ManagementNetworksDepressionAsthmaType 1diabetesAlzheimer’sDiseases with immediate consequencesType 2diabetesChronic back painAddiction:Smoking,alcohol etc.ObesityFacilitated PatientNetworksPatients will probably notadhere but participate at theirown volition in networksBehaviour dependent / influenced diseasesPatients are likely tohave relatively lowadherence rates andneed to bemotivatedto participate innetworksMinimalDegree to which behaviour change is requiredExtensiveSource: The Innovator’s prescription, Christensen, Booz & Company AnalysisBooz & Company 14 November 2011 Prepared for Novo Nordisk4653
Page 6 and 7: SummaryDiabetes is a serious and de
Page 8: diabetes care. Extra compensation w
Page 11 and 12: ContentsSummarized findings and rec
Page 13 and 14: 11Diabetes is a major and underesti
Page 15 and 16: 33Further improving health of of di
Page 17 and 18: 22Recommendation 2: Engage employer
Page 19 and 20: 44Recommendation 4: Introduce condi
Page 21 and 22: Already more than 1M diabetes patie
Page 23 and 24: Costs of of complications and treat
Page 25 and 26: Number of patients reaches ~1.4M in
Page 27 and 28: Increase in lost productivity is dr
Page 29 and 30: Diabetes care clearly improved in t
Page 31 and 32: Better compliance can be stimulated
Page 37 and 38: Delaying complications saves medica
Page 39 and 40: LimitedLimitedcollaborationcollabor
Page 41 and 42: Individual quality incentives are l
Page 43 and 44: Recommendation 1: Insurer should in
Page 47 and 48: Labour shortage from late nineties
Page 49 and 50: However, curative and participative
Page 53: Non-compliance leads to severe comp
Page 58 and 59: Recommendation 3:Facilitate network
Page 62 and 63: But new medication could add a lot
Page 66: Booz & Company is a global manageme

Diabetes Care in The Netherlands: - Novo Nordisk

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?